Tirzepatide · source year
6 selected, source-linked Tirzepatide records carrying a 2023 source date. This is a navigational view of PeptideScanner’s selected coverage—not a complete research timeline or a statement about safety or effectiveness.
6 selected records.
2 represented types.
6 distinct public records.
Cited chronology
Regulatory
DailyMed lists Structured Product Labeling version 3 for the reviewed Tirzepatide label family with a published date of 2023-11-16. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
Regulatory
DailyMed lists Structured Product Labeling version 2 for the reviewed Tirzepatide label family with a published date of 2023-11-14. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
Regulatory
The official Drugs@FDA dataset lists original submission 1 for NDA 217806 with status AP dated 2023-11-08, and names tirzepatide among the application record's active ingredients.
Source: Drugs@FDA via openFDA ↗
Regulatory
The Federal Register published notice 2023-18026, attributed to FDA and its parent HHS department, on 2023-08-22. Its official title is “Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Glucagon and Tirzepatide.
Source: Federal Register via GovInfo ↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT04172987 at 2026-07-30T19:15:14.513Z. Its registry update date was 2023-03-27, and PeptideScanner's reviewed identity mapping was tirzepatide.
Source: ClinicalTrials.gov ↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT03940742 at 2026-07-30T19:15:14.510Z. Its registry update date was 2023-03-24, and PeptideScanner's reviewed identity mapping was tirzepatide.
Source: ClinicalTrials.gov ↗